Cover Image
Market Research Report

Hepatitis D - Market Insights, Epidemiology and Market Forecast-2028

Published by DelveInsight Business Research LLP Product code 534760
Published Content info 100 Pages
Delivery time: 1-2 business days
Price
Back to Top
Hepatitis D - Market Insights, Epidemiology and Market Forecast-2028
Published: January 1, 2019 Content info: 100 Pages
Description

DelveInsight's 'Hepatitis D - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Hepatitis D in the United States, EU5 (France, Germany, Italy, Spain and United Kingdom), Japan and China.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Hepatitis D from 2016 to 2028 segmented by eight major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to find best of the opportunities and assess underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (France, Germany, Italy, Spain and the United Kingdom)
  • Japan
  • China

Study Period: 2016-2028

Hepatitis D - Disease Understanding and Treatment Algorithm

The DelveInsight Hepatitis D market report gives the thorough understanding of Hepatitis D by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Hepatitis D in the US, Europe and Japan and China.

Hepatitis D Epidemiology

The Hepatitis D epidemiology division provide the insights about historical and current patient pool and forecasted trend for each of the 8 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [total prevalent cases, prevalence by Severity (Fulminant, Acute & Chronic), Gender Specific prevalence, Age Specific prevalence and diagnosed cases] of Hepatitis-D in the 8MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), Japan and China from 2016-2028.

According to DelveInsight, total prevalent population of Hepatitis D in 8 major markets was estimated to be 10,546,938 in 2016.

Hepatitis D Drug Chapters

This segment of Hepatitis D report encloses the detailed analysis of marketed drugs and late stage (Phase-III & Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

There is no cure or vaccine for Hepatitis D and the current market is based on the use of antiviral nucleotide analogs, conventional interferon and off-label use of pegylated Interferon. There is not much progress in treatment methods for Hepatitis D after Interferons, only off-label use of pegylated Interferon has reduced the doses of conventional interferon from thrice a week to once a week. To overcome the shortcomings of current treatment market different companies are working robustly with promising drug candidates in different target areas to bring an effective therapy to the market.

Detailed chapters for all the upcoming therapies i.e., Pegasys (Hoffmann-La Roche), Pegylated interferon lambda 1a (Eiger Biopharmaceuticals Inc.), Myrcludex B (MYR Pharma), Lonafarnib (Eiger Bio-Pharmaceuticals), REP 2139-Ca (Replicor Inc.) etc., have been covered in the report.

Hepatitis D Market Outlook

The Hepatitis D market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of off-label therapies, marketed therapies and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the global market of Hepatitis D was estimated to be USD 656 Million in 2016, and is expected to increase at a CAGR of XX% from 2016-2028.

Hepatitis D Drugs Uptake

This section focusses on the rate of uptake of the potential drugs that will get launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Hepatitis D Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Hepatitis D Report Key Strengths

  • 10 Year Forecast
  • 8MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analysed Market
  • Key Cross Competition

Hepatitis D Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Hepatitis D market
  • Organize sales and marketing efforts by identifying the best opportunities for Hepatitis D market
  • To understand the future market competition in the Hepatitis D market.
Table of Contents
Product Code: DIMI0101

Table of Contents

1. Key Insights

2. Hepatitis D Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Hepatitis D in 2016
  • 2.2. Market Share (%) Distribution of Hepatitis D in 2028

3. Disease Background and Overview: Hepatitis D

  • 3.1. Introduction
  • 3.2. Classification
  • 3.3. Factors influencing Hepatitis D Progression
  • 3.4. Disease Causes
  • 3.5. HDV-Symptoms
  • 3.6. Pathogenesis
  • 3.7. Pathophysiology
  • 3.8. HDV Diagnosis
  • 3.9. Prevention

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 8MM Prevalent Population of Hepatitis D

5. Country Wise-Epidemiology of Hepatitis D

  • 5.1. United States
    • 5.1.1. Prevalent cases of Hepatitis D in the United States
    • 5.1.2. Prevalent Population of Hepatitis D by severity
    • 5.1.3. Gender Specific Hepatitis D Prevalence
    • 5.1.4. Age Specific Hepatitis D Prevalence
    • 5.1.5. Diagnosed cases of Chronic Hepatitis D
  • 5.2. EU5
    • 5.2.1. Prevalent Population of Hepatitis D in EU5
  • 5.3. France
    • 5.3.1. Prevalent Population of Hepatitis D
    • 5.3.2. Prevalent Population of Hepatitis D by severity
    • 5.3.3. Gender Specific Hepatitis D Prevalence
    • 5.3.4. Age Specific Hepatitis D Prevalence
    • 5.3.5. Diagnosed cases of Chronic Hepatitis D
  • 5.4. Germany
    • 5.4.1. Prevalent Population of Hepatitis D
    • 5.4.2. Prevalent Population of Hepatitis D by severity
    • 5.4.3. Gender Specific Hepatitis D Prevalence
    • 5.4.4. Age Specific Hepatitis D Prevalence
    • 5.4.5. Diagnosed cases of Chronic Hepatitis D
  • 5.5. Italy
    • 5.5.1. Prevalent Population of Hepatitis D
    • 5.5.2. Prevalent Population of Hepatitis D by severity
    • 5.5.3. Gender Specific Hepatitis D Prevalence
    • 5.5.4. Age Specific Hepatitis D Prevalence
    • 5.5.5. Diagnosed cases of Chronic Hepatitis D
  • 5.6. Spain
    • 5.6.1. Prevalent Population of Hepatitis D
    • 5.6.2. Prevalent Population of Hepatitis D by severity
    • 5.6.3. Gender Specific Hepatitis D Prevalence
    • 5.6.4. Age Specific Hepatitis D Prevalence
    • 5.6.5. Diagnosed cases of Chronic Hepatitis D
  • 5.7. United Kingdom
    • 5.7.1. Prevalent Population of Hepatitis D
    • 5.7.2. Prevalent Population of Hepatitis D by severity
    • 5.7.3. Gender Specific Hepatitis D Prevalence
    • 5.7.4. Age Specific Hepatitis D Prevalence
    • 5.7.5. Diagnosed cases of Chronic Hepatitis D
  • 5.8. Japan
    • 5.8.1. Prevalent Population of Hepatitis D
    • 5.8.2. Prevalent Population of Hepatitis D by severity
    • 5.8.3. Gender Specific Hepatitis D Prevalence
    • 5.8.4. Age Specific Hepatitis D Prevalence
    • 5.8.5. Diagnosed cases of Chronic Hepatitis D
  • 5.9. China
    • 5.9.1. Prevalent Population of Hepatitis D
    • 5.9.2. Prevalent Population of Hepatitis D by severity
    • 5.9.3. Gender Specific Hepatitis D Prevalence
    • 5.9.4. Age Specific Hepatitis D Prevalence
    • 5.9.5. Diagnosed cases of Chronic Hepatitis D

6. Current Treatment Practices

7. Treatment Algorithm

8. Unmet needs

9. Emerging Therapies

  • 9.1. Key Cross Competition
  • 9.2. Phase II Drugs
  • 9.3. Pegasys: Hoffmann-La Roche
    • 9.3.1. Drug Description
    • 9.3.2. Product Profile
    • 9.3.3. Clinical Development
    • 9.3.4. Clinical Trials Information
    • 9.3.5. Safety and efficacy
    • 9.3.6. Advantages and Disadvantages
  • 9.4. REP 2139-Ca + Pegasys: Replicor Inc.
    • 9.4.1. Drug Description
    • 9.4.2. Product Profile
    • 9.4.3. Other Development Activities
    • 9.4.4. Clinical Development
    • 9.4.5. Clinical Trials Information
    • 9.4.6. Safety and Efficacy
    • 9.4.7. Advantages and disadvantages
  • 9.5. Myrcludex B: MYR Pharma
    • 9.5.1. Drug Description
    • 9.5.2. Product Profile
    • 9.5.3. Other Development Activities
    • 9.5.4. Clinical Development
    • 9.5.5. Clinical Trials Information
    • 9.5.6. Safety and efficacy
    • 9.5.7. Advantages and disadvantages
  • 9.6. Lonafarnib: Eiger BioPharmaceuticals
    • 9.6.1. Drug Description
    • 9.6.2. Product Profile
    • 9.6.3. Regulatory milestones
    • 9.6.4. Clinical Development
    • 9.6.5. Clinical Trials Information
    • 9.6.6. Safety and efficacy
    • 9.6.7. Advantages and Disadvantages
  • 9.7. Pegylated interferon lambda 1a: Eiger BioPharmaceuticals
    • 9.7.1. Drug Description
    • 9.7.2. Product Profile
    • 9.7.3. Other development activities
    • 9.7.4. Clinical Development
    • 9.7.5. Clinical Trials Information
    • 9.7.6. Safety and efficacy
    • 9.7.7. Advantages and Disadvantages

10. Hepatitis D: Market Analysis

11. Key Findings

  • 11.1. Hepatitis D: Total Market Size in 8MM
  • 11.2. Total Market Size of Hepatitis D in 8MM
  • 11.3. Therapy Based Market Size of Hepatitis D in 8MM

12. Market Size of Hepatitis D by Country

  • 12.1. United States Market Analysis
    • 12.1.1. Market Size of Hepatitis D in the US
    • 12.1.2. Therapy Based Market Size of Hepatitis D in the US
  • 12.2. Hepatitis D: EU5 Market Outlook
  • 12.3. Germany
    • 12.3.1. Market Size of Hepatitis D in Germany
    • 12.3.2. Therapy Based Market Size of Hepatitis D in Germany
  • 12.4. France
    • 12.4.1. Market Size of Hepatitis D in France
    • 12.4.2. Therapy Based Market Size of Hepatitis D in France
  • 12.5. Italy
    • 12.5.1. Market Size of Hepatitis D in Italy
    • 12.5.2. Therapy Based Market Size of Hepatitis D in Italy
  • 12.6. United Kingdom
    • 12.6.1. Market Size of Hepatitis D in the UK
    • 12.6.2. Therapy Based Market Size of Hepatitis D in the UK
  • 12.7. Spain
    • 12.7.1. Market Size of Hepatitis D in Spain
    • 12.7.2. Therapy Based Market Size of Hepatitis D in Spain
  • 12.8. Japan: Market Analysis
    • 12.8.1. Market Size of Hepatitis D in Japan
    • 12.8.2. Therapy Based Market Size of Hepatitis D in Japan
  • 12.9. China: Market Analysis
    • 12.9.1. Market Size of Hepatitis D in China
    • 12.9.2. Therapy Based Market Size of Hepatitis D in China

13. Market Drivers of Hepatitis D

14. Market Barriers of Hepatitis D

15. Appendix

16. Report Methodology

  • 16.1. Sources Used

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

List of Tables

  • Table 1: 8MM, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
  • Table 2: The United States, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
  • Table 3: The United States, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
  • Table 4: The United States, Gender-Specific Hepatitis D Prevalence, 2016-2028
  • Table 5: The United States, Age-Specific Hepatitis D Prevalence, 2016-2028
  • Table 6: The United States, Diagnosed cases of Hepatitis D, 2016-2028
  • Table 7: EU5, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
  • Table 8: France, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
  • Table 9: France, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
  • Table 10: France, Gender Specific Hepatitis D Prevalence, 2016-2028
  • Table 11: France, Age Specific Hepatitis D Prevalence, 2016-2028
  • Table 12: France, Diagnosed cases of Hepatitis D, 2016-2028
  • Table 13: Germany, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
  • Table 14: Germany, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
  • Table 15: Germany, Gender-Specific Hepatitis D Prevalence, 2016-2028
  • Table 16: Germany, Age-Specific Hepatitis D Prevalence, 2016-2028
  • Table 17: Germany, Diagnosed cases of Hepatitis D, 2016-2028
  • Table 18: Italy, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
  • Table 19: Italy, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
  • Table 20: Italy, Gender-Specific Hepatitis D Prevalence, 2016-2028
  • Table 21: Italy, Age-Specific Hepatitis D Prevalence, 2016-2028
  • Table 22: Italy, Diagnosed cases of Hepatitis D, 2016-2028
  • Table 23: Spain, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
  • Table 24: Spain, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
  • Table 25: Spain, Gender Specific Hepatitis D Prevalence, 2016-2028
  • Table 26: Spain, Age Specific Hepatitis D Prevalence, 2016-2028
  • Table 27: Spain, Diagnosed cases of Hepatitis D, 2016-2028
  • Table 28: The United Kingdom, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
  • Table 29: The United Kingdom, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
  • Table 30: The United Kingdom, Gender Specific Hepatitis D Prevalence, 2016-2028
  • Table 31: The United Kingdom, Age-Specific Hepatitis D Prevalence, 2016-2028
  • Table 32: The United Kingdom, Diagnosed cases of Hepatitis D, 2016-2028
  • Table 33: Japan, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
  • Table 34: Japan, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
  • Table 35: Japan, Gender Specific Hepatitis D Prevalence, 2016-2028
  • Table 36: Japan, Age Specific Hepatitis D Prevalence, 2016-2028
  • Table 37: Japan, Diagnosed cases of Hepatitis D, 2016-2028
  • Table 38: China, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
  • Table 39: China, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
  • Table 40: China, Gender Specific Hepatitis D Prevalence, 2016-2028
  • Table 41: China, Age Specific Hepatitis D Prevalence, 2016-2028
  • Table 42: China, Diagnosed cases of Hepatitis D, 2016-2028
  • Table 43: Phase I/II drug analysis
  • Table 44: Pegasys, Clinical Trial Description, 2016
  • Table 45: REP 2139, Clinical Trial Description, 2016
  • Table 46: Myrcludex B, Clinical Trial Description, 2016
  • Table 47: Lonafarnib, Clinical Trial Description, 2016
  • Table 48: Lambda, Clinical Trial Description, 2016
  • Table 49: 8 Major Market Size of Hepatitis D in USD Million (2016-2028)
  • Table 50: Therapy Based Market Size of Hepatitis D in 8MM in USD Million (2016-2028)
  • Table 51: Market Size of Hepatitis D in the US, USD Million (2016-2028)
  • Table 52: Therapy Based Market Size of Hepatitis D in the US in USD Million (2016-2028)
  • Table 53: Market Size of Hepatitis D in Germany, USD Million (2016-2028)
  • Table 54: Therapy Based Market Size of Hepatitis D in Germany in USD Million (2016-2028)
  • Table 55: Market Size of Hepatitis D in France, USD Million (2016-2028)
  • Table 56: Therapy Based Market Size of Hepatitis D in France in USD Million (2016-2028)
  • Table 57: Market Size of Hepatitis D in Italy, USD Million (2016-2028)
  • Table 58: Therapy Based Market Size of Hepatitis D in Italy in USD Million (2016-2028)
  • Table 59: Market Size of Hepatitis D in the UK, USD Million (2016-2028)
  • Table 60: Therapy Based Market Size of Hepatitis D in the UK in USD Million (2016-2028)
  • Table 61: Market Size of Hepatitis D in Spain, USD Million (2016-2028)
  • Table 62: Therapy Based Market Size of Hepatitis D in Spain in USD Million (2016-2028)
  • Table 63: Market Size of Hepatitis D in Japan, USD Million (2016-2028)
  • Table 64: Therapy Based Market Size of Hepatitis D in Japan in USD Million (2016-2028)
  • Table 65: Market Size of Hepatitis D in China, USD Million (2016-2028)
  • Table 66: Therapy Based Market Size of Hepatitis D in China in USD Million (2016-2028)

List of Figures

  • Figure 1: Hepatitis Delta Virus Structure
  • Figure 2: Pathogenesis of Hepatitis D
  • Figure 3: Diagnostic markers in various hepatitis D disease patterns
  • Figure 4: 8MM, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
  • Figure 5: The United States, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
  • Figure 6: The United States, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
  • Figure 7: The United States, Gender-Specific Hepatitis D Prevalence, 2016-2028
  • Figure 8: The United States, Age Specific Hepatitis D Prevalence, 2016-2028
  • Figure 9: The United States, Diagnosed cases of Hepatitis D, 2016-2028
  • Figure 10: EU5, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
  • Figure 11: France, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
  • Figure 12: France, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
  • Figure 13: France, Gender Specific Hepatitis D Prevalence, 2016-2028
  • Figure 14: France, Age-specific Hepatitis D Prevalence, 2016-2028
  • Figure 15: France, Diagnosed cases of Hepatitis D, 2016-2028
  • Figure 16: Germany, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
  • Figure 17: Germany, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
  • Figure 18: Germany, Gender-Specific Hepatitis D Prevalence, 2016-2028
  • Figure 19: Germany, Age-Specific Hepatitis D Prevalence, 2016-2028
  • Figure 20: Germany, Diagnosed cases of Hepatitis D, 2016-2028
  • Figure 21: Italy, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
  • Figure 22: Italy, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
  • Figure 23: Italy, Gender-Specific Hepatitis D Prevalence, 2016-2028
  • Figure 24: Italy, Age-Specific Hepatitis D Prevalence, 2016-2028
  • Figure 25: Italy, Diagnosed cases of Hepatitis D, 2016-2028
  • Figure 26: Spain, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
  • Figure 27: Spain, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
  • Figure 28: Spain, Gender Specific Hepatitis D Prevalence, 2016-2028
  • Figure 29: Spain, Age Specific Hepatitis D Prevalence, 2016-2028
  • Figure 30: Spain, Diagnosed cases of Hepatitis D, 2016-2028
  • Figure 31: The United Kingdom, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
  • Figure 32: The United Kingdom, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
  • Figure 33: The United Kingdom, Gender-Specific Hepatitis D Prevalence, 2016-2028
  • Figure 34: The United Kingdom, Age Specific Hepatitis D Prevalence, 2016-2028
  • Figure 35: The United Kingdom, Diagnosed cases of Hepatitis D, 2016-2028
  • Figure 36: Japan, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
  • Figure 37: Japan, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
  • Figure 38: Japan, Gender Specific Hepatitis D Prevalence, 2016-2028
  • Figure 39: Japan, Age Specific Hepatitis D Prevalence, 2016-2028
  • Figure 40: Japan, Diagnosed cases of Hepatitis D, 2016-2028
  • Figure 41: China, Historical & Forecasted Hepatitis D Prevalence, 2016-2028
  • Figure 42: China, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028
  • Figure 43: China, Gender Specific Hepatitis D Prevalence, 2016-2028
  • Figure 44: China, Age Specific Hepatitis D Prevalence, 2016-2028
  • Figure 45: China, Diagnosed cases of Hepatitis D, 2016-2028
  • Figure 46: Suggested Algorithm for Investigation and Treatment
  • Figure 47: Diagnosis and Treatment of Hepatitis Delta Virus (HDV) infection
  • Figure 48: Treatment algorithm
  • Figure 49: Unmet Needs of HDV
  • Figure 50: 8 Major Market Size of Hepatitis D in USD Million (2016-2028)
  • Figure 51: Therapy Based Market Size of Hepatitis D in 8MM in USD Million (2016-2028)
  • Figure 52: Market Size of Hepatitis D in the US, USD Million (2016-2028)
  • Figure 53: Therapy Based Market Size of Hepatitis D in the US in USD Million (2016-2028)
  • Figure 54: Market Size of Hepatitis D in Germany, USD Million (2016-2028)
  • Figure 55: Therapy Based Market Size of Hepatitis D in Germany in USD Million (2016-2028)
  • Figure 56: Market Size of Hepatitis D in France, USD Million (2016-2028)
  • Figure 57: Therapy Based Market Size of Hepatitis D in France in USD Million (2016-2028)
  • Figure 58: Market Size of Hepatitis D in Italy, USD Million (2016-2028)
  • Figure 59: Therapy Based Market Size of Hepatitis D in Italy in USD Million (2016-2028)
  • Figure 60: Market Size of Hepatitis D in the UK, USD Million (2016-2028)
  • Figure 61: Therapy Based Market Size of Hepatitis D in The UK in USD Million (2016-2028)
  • Figure 62: Market Size of Hepatitis D in Spain, USD Million (2016-2028)
  • Figure 63: Therapy Based Market Size of Hepatitis D in Spain in USD Million (2016-2028)
  • Figure 64: Market Size of Hepatitis D in Japan, USD Million (2016-2028)
  • Figure 65: Therapy Based Market Size of Hepatitis D in Japan in USD Million (2016-2028)
  • Figure 66: Market Size of Hepatitis D in China, USD Million (2016-2028)
  • Figure 67: Therapy Based Market Size of Hepatitis D in China in USD Million (2016-2028)
  • Figure 68: Market Drivers of HDV
  • Figure 69: Market Barriers of HDV
Back to Top